PL3445351T3 - Acetyloleucyna lub jej farmaceutycznie dopuszczalna sól do poprawy mobilności - Google Patents

Acetyloleucyna lub jej farmaceutycznie dopuszczalna sól do poprawy mobilności

Info

Publication number
PL3445351T3
PL3445351T3 PL17719692.0T PL17719692T PL3445351T3 PL 3445351 T3 PL3445351 T3 PL 3445351T3 PL 17719692 T PL17719692 T PL 17719692T PL 3445351 T3 PL3445351 T3 PL 3445351T3
Authority
PL
Poland
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
improved mobility
Prior art date
Application number
PL17719692.0T
Other languages
English (en)
Inventor
Mallory Factor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of PL3445351T3 publication Critical patent/PL3445351T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PL17719692.0T 2016-04-19 2017-04-19 Acetyloleucyna lub jej farmaceutycznie dopuszczalna sól do poprawy mobilności PL3445351T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Publications (1)

Publication Number Publication Date
PL3445351T3 true PL3445351T3 (pl) 2025-01-07

Family

ID=58633040

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17719692.0T PL3445351T3 (pl) 2016-04-19 2017-04-19 Acetyloleucyna lub jej farmaceutycznie dopuszczalna sól do poprawy mobilności

Country Status (26)

Country Link
US (4) US10905670B2 (pl)
EP (2) EP4501406A3 (pl)
JP (3) JP7387264B2 (pl)
KR (4) KR102413754B1 (pl)
CN (2) CN118593463A (pl)
AU (2) AU2017252507B2 (pl)
BR (1) BR112018071547A2 (pl)
CA (1) CA3021155A1 (pl)
DK (1) DK3445351T3 (pl)
ES (1) ES2994242T3 (pl)
FI (1) FI3445351T3 (pl)
HR (1) HRP20241552T1 (pl)
HU (1) HUE069219T2 (pl)
IL (3) IL310508A (pl)
LT (1) LT3445351T (pl)
MD (1) MD3445351T2 (pl)
MX (2) MX388461B (pl)
PL (1) PL3445351T3 (pl)
PT (1) PT3445351T (pl)
RS (1) RS66142B1 (pl)
RU (1) RU2745912C2 (pl)
SG (2) SG10202106190RA (pl)
SI (1) SI3445351T1 (pl)
SM (1) SMT202400459T1 (pl)
WO (1) WO2017182802A1 (pl)
ZA (1) ZA201806849B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017182802A1 (en) 2016-04-19 2017-10-26 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
MA43828B1 (fr) 2016-08-11 2019-09-30 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
BR112021010923A2 (pt) 2018-12-06 2021-08-24 Intrabio Ltd Análogos deuterados de acetileucina
KR20250171484A (ko) * 2019-03-02 2025-12-08 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
CN121586570A (zh) * 2023-07-18 2026-02-27 赛泽恩有限公司 调控黑素生成的组合物及方法
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
CA2687107A1 (en) * 2007-05-08 2008-11-13 Northern Innovations And Formulations Corp. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
US20120196257A1 (en) * 2009-08-27 2012-08-02 Joe Verghese Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
WO2017182802A1 (en) * 2016-04-19 2017-10-26 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
MA50399A (fr) * 2017-10-18 2020-08-26 Intrabio Ltd Agents thérapeutiques pour mobilité et fonction cognitive améliorées et pour le traitement de maladies neurodégénératives et de troubles de stockage lysosomal

Also Published As

Publication number Publication date
CA3021155A1 (en) 2017-10-26
PT3445351T (pt) 2024-11-14
IL262379B (en) 2022-07-01
AU2017252507A1 (en) 2018-11-08
JP2019513814A (ja) 2019-05-30
AU2022256077A1 (en) 2022-11-17
SI3445351T1 (sl) 2025-04-30
KR102632670B1 (ko) 2024-02-01
IL293266B2 (en) 2024-07-01
US20230346732A1 (en) 2023-11-02
MX2018012739A (es) 2019-06-17
KR20180134398A (ko) 2018-12-18
HRP20241552T1 (hr) 2025-01-17
FI3445351T3 (fi) 2024-11-18
RU2018140131A3 (pl) 2020-05-14
US20190083438A1 (en) 2019-03-21
SG10202106190RA (en) 2021-07-29
ES2994242T3 (en) 2025-02-05
RU2745912C2 (ru) 2021-04-02
IL310508A (en) 2024-03-01
EP3445351A1 (en) 2019-02-27
IL262379A (en) 2018-11-29
MX388461B (es) 2025-03-20
US11998518B2 (en) 2024-06-04
US12329733B2 (en) 2025-06-17
RU2021107001A (ru) 2021-04-12
US20210106548A1 (en) 2021-04-15
EP4501406A3 (en) 2025-03-26
JP7506046B2 (ja) 2024-06-25
IL293266A (en) 2022-07-01
MX2021014844A (es) 2022-01-18
SG11201809031XA (en) 2018-11-29
KR20240018683A (ko) 2024-02-13
IL293266B1 (en) 2024-03-01
LT3445351T (lt) 2024-11-25
HUE069219T2 (hu) 2025-02-28
CN109069463A (zh) 2018-12-21
MD3445351T2 (ro) 2024-12-31
US20250332133A1 (en) 2025-10-30
RU2018140131A (ru) 2020-05-14
SMT202400459T1 (it) 2025-01-14
JP2024123087A (ja) 2024-09-10
BR112018071547A2 (pt) 2019-03-06
AU2017252507B2 (en) 2022-07-21
EP4501406A2 (en) 2025-02-05
KR102413754B1 (ko) 2022-06-27
EP3445351B1 (en) 2024-10-16
CN109069463B (zh) 2024-07-23
KR20220038814A (ko) 2022-03-29
KR20220093386A (ko) 2022-07-05
RS66142B1 (sr) 2024-12-31
JP2022024058A (ja) 2022-02-08
DK3445351T3 (da) 2024-11-04
CN118593463A (zh) 2024-09-06
ZA201806849B (en) 2019-07-31
JP7387264B2 (ja) 2023-11-28
US10905670B2 (en) 2021-02-02
WO2017182802A1 (en) 2017-10-26
KR102791288B1 (ko) 2025-04-03
NZ747307A (en) 2025-10-31

Similar Documents

Publication Publication Date Title
NO2026004I1 (no) Sebetralstat or a pharmaceutically acceptable salt or solvate thereof
NO2025044I1 (no) Inavolisib or a pharmaceutically acceptable salt thereof
NO2025038I1 (no) Risdiplam or a pharmaceutically acceptable salt thereof - forlenget
NO2022058I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
NO2026006I1 (no) Elinzanetant or a pharmaceutically acceptable salt thereof
NO2024009I1 (no) Gefapixant, or a pharmaceutically acceptable salt thereof
IL266017A (en) Pharmaceutical compounds
GB201612092D0 (en) Pharmaceutical compounds
GB201617758D0 (en) Pharmaceutical compounds
ZA201900540B (en) Pharmaceutical compounds
FIC20253004I1 (fi) Seladelpaari tai sen farmaseuttisesti hyväksyttävä suola, erityisesti seladelpaari-L-lysiinidihydraatti
GB201519352D0 (en) Pharmaceutical compounds
EP3638658C0 (en) PHARMACEUTICAL COMPOUNDS
LT3445351T (lt) Acetil-leucinas arba farmaciniu požiūriu priimtina jo druska, skirti judrumo pagerinimui
GB201617454D0 (en) Pharmaceutical compounds
GB201704714D0 (en) Pharmaceutical compounds
GB201617627D0 (en) Pharmaceutical compounds
GB201612095D0 (en) Pharmaceutical compounds
GB201704965D0 (en) Pharmaceutical compounds
GB201703881D0 (en) Pharmaceutical compounds
IL256339B (en) A derivative of pyrazole or its pharmacy salt
ZA201904241B (en) Novel compound and pharmacologically acceptable salt thereof
NO2024058I1 (no) delgocitinib or a pharmaceutically acceptable salt thereof
GB201704966D0 (en) Pharmaceutical compounds
GB201617871D0 (en) Pharmaceutical compounds